Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Seeking Alpha

31 Jul 2026, 15:34 UTC · 22h ago

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

What the story claims

4 claims · each scored for market impact

What matters in this story

1
LIFYORLI generated $47.6M in its first full quarter with a projected US peak revenue exceeding $1B. — Strong initial commercial traction and high peak revenue targets provide a fundamental growth catalyst for the company.
+0.60
2
Relacorilant is pending EU approval and being explored for earlier PROC lines. — Regulatory approval in a new region and expansion into earlier lines of treatment offer significant pipeline upside.
+0.40
3
Corcept's current valuation is considered premium, with strong LIFYORLI demand already priced in. — A premium valuation limits further short-term upside and increases the risk of a pullback if expectations aren't exceeded.
-0.30
4

6 related stories

Newsfile Corp
1h ago
ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm - ADMA
- biotech
- pharmaceuticals
Read

Corcept Therapeutics: LIF… — CORT +0.20 | NewsImpactScreener

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

What matters in this story

ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm - ADMA

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

What matters in this story

ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm - ADMA

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That

ERASCA DEADLINE: ROSEN, A TRUSTED INVESTOR RIGHTS FIRM, Encourages Erasca, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action - ERAS

Apple's Safe Haven Illusion Faces an Impending Hangover

Garrett Motion: Positive Q2 Results Point To Strong Future Growth

Both Berkshire Hathaway and Micron Stocks Look Cheap on the Surface. But I Like 1 Better Than the Other.

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

What matters in this story

Next reads from the same story arc

ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm - ADMA

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

What matters in this story

Next reads from the same story arc

ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm - ADMA

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That

ERASCA DEADLINE: ROSEN, A TRUSTED INVESTOR RIGHTS FIRM, Encourages Erasca, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action - ERAS

Apple's Safe Haven Illusion Faces an Impending Hangover

Garrett Motion: Positive Q2 Results Point To Strong Future Growth

Both Berkshire Hathaway and Micron Stocks Look Cheap on the Surface. But I Like 1 Better Than the Other.